<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="3" ids="16335">Adenosine</z:chebi> A3 receptor (A3R) <z:chebi fb="4" ids="48705">agonists</z:chebi> have been shown to reduce cardiac and lung injury, but the protective roles of A3R <z:chebi fb="4" ids="48705">agonists</z:chebi> in the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> are not well characterized </plain></SENT>
<SENT sid="1" pm="."><plain>The protective effect of selective A3R <z:chebi fb="4" ids="48705">agonist</z:chebi> chloro-N(6)-(3-<z:chebi fb="0" ids="43448">iodo</z:chebi>-<z:chebi fb="0" ids="22744">benzyl</z:chebi>)-<z:chebi fb="3" ids="16335">adenosine</z:chebi>-5'-N-methyluronamide (Cl-IB-MECA) was first examined in primary cortical cultures </plain></SENT>
<SENT sid="2" pm="."><plain>In cortical culture, Cl-IB-MECA pretreatment antagonized the <z:mp ids='MP_0005039'>hypoxia</z:mp>-mediated decrease in cell viability </plain></SENT>
<SENT sid="3" pm="."><plain>In vivo, Cl-IB-MECA or vehicle was given intracerebroventricularly or intravenously to anesthetized rats </plain></SENT>
<SENT sid="4" pm="."><plain>Animals were subjected to focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> induced by transient middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) ligation </plain></SENT>
<SENT sid="5" pm="."><plain>Intracerebroventricular or repeated intravenous administration (i.e., at 165 min and 15 min before <z:chebi fb="70" ids="34342">MCA</z:chebi> ligation) of Cl-IB-MECA did not alter blood pressure during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> but <z:mp ids='MP_0001399'>increased locomotor activity</z:mp> and decreased <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> 2 days after </plain></SENT>
<SENT sid="6" pm="."><plain>In these animals, Cl-IB-MECA also reduced the density of TUNEL labeling in the lesioned cortex </plain></SENT>
<SENT sid="7" pm="."><plain>The possibility of endogeneous neuroprotection was further examined in A3R knockout mice </plain></SENT>
<SENT sid="8" pm="."><plain>After <z:chebi fb="70" ids="34342">MCA</z:chebi> ligation, an increase in <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> was found in the A3R knockouts compared with the A3R <z:mp ids='MP_0002169'>wild-type</z:mp> controls, suggesting that A3Rs are tonically activated during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Additionally, intracerebroventricular pretreatment with Cl-IB-MECA decreased the size of infarction in the <z:mp ids='MP_0002169'>wild-type</z:mp> controls, but not in the A3R knockout animals, suggesting that Cl-IB-MECA-induced protection was mediated through the A3 receptors </plain></SENT>
<SENT sid="10" pm="."><plain>Collectively, these data suggest that Cl-IB-MECA reduced <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> through the activation of A3Rs and suppression of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
</text></document>